You cannot reverse engineer your human factors regulatory strategy at the 11th hour.
FDA’s new human factors guidance is not just about what goes into a marketing submission. It changes the way teams need to think about use-related risk, critical tasks, labeling, training, post-market evidence, and design change control across the product lifecycle.
In this audio case study, we walk through why Category 3 human factors validation may become the default concern when critical tasks are introduced or impacted and why Decision Point D is not a shortcut, but an evidence-based exception that depends on history of use, user interface complexity, and the adequacy of existing risk controls.
Key highlights covered in the audio:
* Why human factors can no longer be treated as a late-stage submission activity
* How use-related risk analysis drives the identification of critical tasks
* Why Category 3 validation may be triggered by more than obvious design changes
* How Decision Point D may reduce submission burden — but only with strong evidence
* Why post-market surveillance data now has direct pre-market strategic value
Keywords:
FDA human factors guidance, medical device marketing submissions, use-related risk analysis, critical tasks, Category 3 human factors validation, Decision Point D, eSTAR, QMSR, medical device usability, post-market surveillance, design validation, medical device labeling.
🎧Click Play above to listen to a brief audio summary about this case and lessons QA/RA and Clinical professionals can apply in practice using the newly released FDA Guidance.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.
Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026, May 29), Content of Human Factors Information in Medical Device Marketing Submissions, Final Guidance, FDA.
* Al-Faruque, F. (2026, May 28). FDA provides additional examples, clarity in human factors guidance. Regulatory Affairs Professionals Society (RAPS).
* Lenz, A. R. (2026, June 3). FDA Issues Final Guidance for Content of Human Factors Information in Medical Device Submissions. FDA Law Blog.
* Pure Global. (2026, June 2). FDA Human Factors Guidance 2026 Update for Device Submissions. Pure Global Regulatory News.
* Regulatory Evolution of Human Factors in Medical Device Submissions: A Comprehensive Analysis of the Final FDA Guidance and Its Quality System Implications. (2026).
* Strochlic, A. (2026, May 29). Key Updates in the Final FDA Guidance: Content of Human Factors Information in Medical Device Marketing Submissions (2026). Emergo by UL.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
